Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan

Annals of Internal Medicine

Volumn 131, Issue 3, 1999, Pages 174-181

  Yoshida, Haruhiko ^a   Shiratori, Yasushi ^a   Moriyama, Mitsuhiko ^b   Arakawa, Yasuyuki ^b   Ide, Tatsuya ^c   Sata, Michio ^c   Inoue, Osami ^d   Yano, Michitami ^d   Tanaka, Motohiko ^e   Fujiyama, Shigetoshi ^e   Nishiguchi, Shuhei ^f   Kuroki, Tetsuo ^f   Imazeki, Fumio ^g   Yokosuka, Osamu ^g   Kinoyama, Shingo ^h   Yamada, Gotaro ^h   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Nagasaki Chuo National Hospital   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f Osaka Prefecture University   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER RISK; DISEASE SEVERITY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; JAPAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD;

EID: 0033520109     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-3-199908030-00003     Document Type: Article

References (36)

1. Yokosuka O, Kato N, Hosoda K, Ito Y, Imazeki F, Ohto M, et al. Efficacy of longterm Interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut. 1995;37: 721-6.
2. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-40.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Lancet. 1997;349:825-32.
4. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer. 1994;74:2234-8.
5. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650-5.
6. Yamada G, Tanaka E, Miura T, Kiyosawa K, Yano M, Matsushima T, et al. Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: a multi-institution analysis. J Gastroenterol Hepatol. 1995;10:538-45.
7. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 1995;15:64-9.
8. Hoofnagle JH, Mullen KD, Jones B, Rustgi V, Di Bisceglie AM, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;615:1575-8.
9. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-6.
10. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med. 1989; 321:1506-10.
11. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. 1997;113:558-66.
12. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatits Cooperative Study Group. Gastroenterology. 1994;107:805-11.
13. Kawano S, Tanaka M, Fujiyama S, Sato S, Taura Y, Goto M, et al. Clinical usefulness of an assay for hepatitis C virus core in the diagnosis of non-A, non-B hepatitis and monitoring of the response to interferon therapy. J Gastroenterol Hepatol. 1994;9:217-22.
14. Yamada G, Takahashi M, Endo H, Doi T, Miyamoto R, Shimomura H, et al. Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa. Gut. 1993;34(2 Suppl):S133-4.
15. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-89.
16. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Hakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepato-cellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346:1051-5.
17. Yoshida H, Omata M, Arakawa Y, Yokosuka O, Kuroki T, Sata M, et al. Prospective and retrospective multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT): protocol and a preliminary report. In: Tahara E, Sugimachi K, Oohara T, eds. Recent Advances in Gastroenterological Carcinogenesis. Bologna, Italy: Monduzzi Editore; 1996:543-5.
18. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci. 1991;36:1217-22.
19. Takeda T, Kuroki T, Fukuda K, Yabusako T, Nishiguchi S, Nakajima S, et al. Long-term therapeutic efficacy of interferon for patients with chronic hepatitis C. Gastroenterol Jpn. 1993;2B Suppl 5:104-8.
20. Shiratori Y, Kato N, Tamatsukuri S, Yoshida H, Kawabe T, Nakata R, et al. Real-time monitoring of HCV-RNA by single tube assay kit and potential importance for predicting virological sustained response in patients with chronic hepatitis C. J Gastroenterol Hepatol. 1996;11:705-11.
21. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 1995;22:1351-4.
22. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993;341:1501-4.
23. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993; 18:16-20.
24. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugal Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73:673-9.
25. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. M. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 1994;19:1347-53.
26. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19:1513-20.
27. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 1995;21:918-22.
28. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-40.
29. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394-402.
30. Mazella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-7.
31. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-5.
32. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94-9.
33. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995;122:161-8.
34. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology. 1996;111:119-205.
35. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688-94.
36. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Ann Intern Med. 1996;124:1058-60.